Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1552568
PUBLISHER: Grand View Research | PRODUCT CODE: 1552568
Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Multiple Myeloma Therapeutics Market Growth & Trends:
The global multiple myeloma therapeutics market size was valued at USD 30.30 billion in 2030 and is projected to grow at a CAGR of 5.5% from 2024 to 2030. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.
This space is expected to gain momentum with the addition of novel drugs to the current therapeutics array with monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatis faction and increase life expectancies of patients; which in turn is expected to boost the research and development of improved therapies for multiple myeloma.
Growing prevalence of the disease along with the surging elderly population is the prime factor expected to drive the growth significantly during the forecast period. Complications involved in treating geriatric patients are driving the demand for supportive treatments such as restoration procedures involving transfusion of blood components and point of care technologies.
The U.S, followed by Europe, has been dominating the market owing to the presence of major players in these regions, faster approval rates, and favorable healthcare policies. Higher prevalence of multiple myeloma in the developed economies is a pivotal determinant driving the growth of the Europe market.
The space consists of a few major players including Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, and Novartis AG. A large revenue share is captured by Celgene Corporation with its high-performing drug, Revlimid. The drug currently dominates the market with more than 50% share of the total multiple myeloma therapeutics market.
Multiple Myeloma Therapeutics Market Report Highlights:
- According to the National Cancer Institute, more than 30,330 new cases of multiple myelomaare expected to register in 2016. The number of new cases is expected to grow each year with the growing geriatric population.
- Newly introduced drugs are expected to increase the longevity of patients undergoing treatment for multiple myeloma, which yields a high cumulative number of patients requiring treatment each year.
- In 2015, the chemotherapy and other drugs segment dominated the global space with largest revenue share owing to lack of effective alternative option.
- Chemotherapy and other drugs segment has been sub-segmented into traditional chemotherapy, immunomodulating agents, protea some inhibitors, HDAC inhibitors, and monoclonal antibodies.
- In 2015, immunomodulating agents drug class captured the largest market share. Absence of comparable alternatives is the prime factor driving the growth of the segment.
- The newly introduced drugs belonging to the classes HDAC inhibitors and monoclonal antibodies are expected to show the fastest growth during the forecast period owing to the effectiveness and safety of these drugs.
Product Code: GVR-4-68039-913-1
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Multiple Myeloma Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Multiple Myeloma Therapeutics Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Multiple Myeloma Therapeutics Market: Drug Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Multiple Myeloma Therapeutics Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Chemotherapy and Other Drugs
- 4.3.1. Chemotherapy and Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.2. Traditional Chemotherapy
- 4.3.2.1. Traditional Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.3. Immunomodulating Agents
- 4.3.3.1. Immunomodulating Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.4. Proteasome Inhibitors
- 4.3.4.1. Proteasome Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.5. Histone Deacetylase (HDAC) Inhibitors
- 4.3.5.1. Histone Deacetylase (HDAC) Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.6. Monoclonal Antibodies
- 4.3.6.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Radiation
- 4.4.1. Radiation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Stem Cell Transplant and Supportive Treatment
- 4.5.1. Stem Cell Transplant and Supportive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Multiple Myeloma Therapeutics Market: Disease Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Multiple Myeloma Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Active Multiple Myeloma
- 5.3.1. Active Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Smoldering Multiple Myeloma
- 5.4.1. Smoldering Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Multiple Myeloma Therapeutics Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Multiple Myeloma Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Hospitals
- 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Clinics
- 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Other
- 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Multiple Myeloma Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Multiple Myeloma Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
- 7.2. North America
- 7.2.1. North America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK.
- 7.3.2.1. UK Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Japan Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
- 7.4.3.1. China Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
- 7.4.5.1. Australia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
- 7.4.6.1. South Korea Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Thailand Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. South Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Saudi Arabia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. UAE Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Johnson & Johnson Services, Inc.
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Novartis AG
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Amgen Inc.
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Sanofi
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Bristol-Myers Squibb Company.
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Takeda Pharmaceutical Company Limited.
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Merck & Co.
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. AbbVie Inc.
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. GLENMARK PHARMACEUTICALS LTD.
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. DAIICHI SANKYO COMPANY, LIMITED
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. bluebird bio, Inc.
- 8.4.11.1. Participant's Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Recent Developments/ Strategic Initiatives
- 8.4.1. Johnson & Johnson Services, Inc.
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.